NEW YORK (GenomeWeb News) – Life Technologies said today that a jury in the US District Court for the Northern District of California has decided in its favor in the second phase of an ongoing patent-infringement suit with Illumina.
After a seven day trial, the jury unanimously decided that Life Tech's Applied Biosystems SOLiD sequencing technology does not infringe a patent at the heart of the dispute, the company said.
Illumina had alleged that the SOLiD system infringed US Patent Nos. 5,969,119; 5,750,341; and 6,306,597. The court had already ruled in August that ABI does not infringe the asserted claims of the '341 and '597 patents. The jury decision announced today clears ABI of infringing the '119 patent.
Kip Miller, president of the genetic systems division at Life Technologies, said in a statement that the company is "pleased" with the decision, which "validate[s] our belief that the SOLiD sequencing system is unique in its design."
Earlier this month, Illumina won the first phase of the trial, in which the jury found that Illumina owns the patents that are the subject of the suit.
An Illumina spokesperson was not available for comment.